普瑞金（Pregene）与Kite达成战略合作

Pregene and Kite Entered into Strategic Collaboration

2025年10月16日，中国深圳 ——深圳普瑞金生物药业股份有限公司（以下简称 “普瑞金”）与吉利德子公司KITE PHARMA,INC.公司（以下简称“Kite”）达成合作，并签署了授权与合作协议。本次全球合作旨在支持并加速下一代原位编辑疗法的研究与开发，致力于优化从早期发现到临床开发的全流程路径，以更高效的方式为患者带来具有潜在改变生命意义的创新疗法。

SHENZHEN, China (October 16, 2025) —— Shenzhen Pregene Biopharma Co., Ltd. (hereinafter referred to as the “Pregene”) has entered into a License and Collaboration Agreement with Kite, a Gilead company, (hereinafter referred to as “Kite”) to support and accelerate the research and development of next-generation in vivo therapies. This global collaboration aims to streamline the path from discovery to clinical development for in vivo therapies with the goal of delivering potentially life-changing medicines to patients sooner and more efficiently.  

根据协议，普瑞金已获得现金首付款，并有权在触发约定里程碑时获得相应付款，同时还将获得基于净销售额的分级销售收益分成。

Under the terms of the collaboration, Pregene has received an upfront cash payment and is also eligible to receive contingent payments tied to milestones and royalties based on the net sales of future products.

普瑞金创始人之一兼首席科学家张继帅博士表示："我们非常高兴与Kite能够携手合作，共同推动新一代原位编辑疗法的研发进程，助力其早日惠及患者。通过此次合作，我们将充分整合Kite在细胞治疗领域的专业积淀和我司的独特优势，携手突破关键技术壁垒，加速概念验证研究的推进，力求更快地将突破性疗法带给患者，特别是在肿瘤、自身免疫性疾病及其他急需创新的疾病领域。

“We are excited to collaborate with Kite to help advance their efforts in delivering next generation in vivo therapies to patients,” said Dr. Zhang Jishuai, CSO and one of the cofounders of Pregene Biopharma. “By combining Kite’s cell therapy expertise with our respective strengths at Pregene, we aim to overcome technical barriers, accelerate proof-of-concept studies, and bring transformative medicines to patients faster, especially in oncology, autoimmune diseases and other areas where innovation is urgently needed.”

关于普瑞金

普瑞金是一家处于临床阶段的生物制药公司，致力于新型细胞疗法的发现与开发，拥有行业领先的细胞和慢病毒制造工艺及技术。凭借其专有的高通量 CAR-T/CAR-NK/TCR-T 药物优化平台以及专有的细胞和慢病毒制造工艺，普瑞金正在开发丰富的临床阶段候选产品，包括多种自体和异体细胞与基因治疗及生物制剂产品。更多信息请访问 www.pregene.com 。

About Pregene

Pregene is a clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies with industry-leading cell and lentivirus manufacturing processes and technology. Leveraging its proprietary high-throughput CAR-T/CAR-NK/TCR-T drug priority platform, and proprietary cell and lentivirus manufacturing processes, Pregene is developing a rich clinical-stage pipeline of multiple autologous and allogeneic C&G therapy and biologics product candidates. Find more at www.pregene.com.